

1 **Title**

2 Effects of plasma rich in growth factors (PRGF) on biomechanical properties of Achilles tendon repair in  
3 sheep

4

5 **ABSTRACT**

6 **Purpose**

7 To assess the biomechanical effects of intra-tendinous injections of PRGF on the healing Achilles tendon  
8 after repair in a sheep model.

9 **Methods**

10 Thirty sheep were randomly assigned into one of the six groups depending on the type of treatment  
11 received (PRGF or placebo) and survival time (2, 4 and 8 weeks). The Achilles tendon injury was  
12 repaired by suturing the tendinous edges employing a three-loop pulley pattern. A trans-articular external  
13 fixation system was then used for immobilization. The PRGF or placebo was administered on a weekly  
14 basis completing a maximum of 3 infiltrations. The force, section and tension values were compared  
15 between the operated and healthy Achilles tendons across all groups.

16 **Results**

17 The PRGF-treated tendons had higher force at eight weeks compared with the placebo group ( $p=0.007$ ).  
18 Between two and four weeks, a significant increase in force in both the PRGF-treated tendon ( $p=0.0027$ )  
19 and placebo group ( $p=0.0095$ ) occurred. No significant differences were found for section ratio between  
20 PRGF-treated tendons and the placebo group for any of the time periods evaluated. At 2 weeks PRGF-  
21 treated tendons had higher tension ratio compared to placebo group tendons ( $p=0.0143$ ). Both PRGF and  
22 placebo treatments significantly improved the force ( $p<0.001$  and  $p=0.0095$ , respectively) and tension  
23 ( $p=0.009$  and  $p=0.0039$ , respectively) ratios at 8 compared to 2 weeks.

24 **Conclusions**

25 The application of PRGF increases Achilles tendon repair strength at 8 weeks compared to the use of  
26 placebo. The use of PRGF does not modify section and tension ratios compared to placebo at 8 weeks.

27 The tension ratio progressively increases between two and eight weeks compared with the placebo. PRGF  
28 can be used in the clinical setting as a complementary therapy to improve the repair strength of acute  
29 Achilles tendon ruptures.

### 30 **Level of Evidence**

31 Not applicable. Controlled laboratory study.

### 32 **Key Terms**

33 Plasma rich growth factors; PRGF; PRP; Achilles tendon repair; Biomechanical properties

34

## 35 **INTRODUCTION**

36

37 Tendon injuries are very common and the Achilles is one of the most commonly involved [2,16]. The  
38 Achilles tendon supports loads 10 times higher than the body weight [25]. Due to its viscoelastic  
39 properties the tendon has high resistance to elongation before the breaking point [20,31]. However, when  
40 the tendon ruptures the healing potential is low because of poor vascularization and low cell metabolic  
41 rate [13]. Therefore, an attempt to improve tendon healing and biomechanical properties seems timely.

42 Platelets are known to have a critical role in the initiation and maintenance of the repair and  
43 regeneration of tissues [3,10]. A large number of growth factors and other biologically active proteins that  
44 play important roles in the process of tendon repair are found inside the alpha granules [3]. The use of  
45 both platelet-rich plasma (PRP) and plasma rich in growth factors (PRGF) has demonstrated to improve  
46 the healing of Achilles tendon injuries [14,17,23,30,32]. PRGF is a specific type of PRP poor in  
47 leukocytes. The main difference with PRP is the method used for obtaining the PRGF and its final  
48 composition [6,14].

49 From a histological standpoint, the use of PRGF on the healing Achilles tendon produced better  
50 nuclei orientation of the tendon fibroblasts, better organization of the collagen fibers, lower inflammatory  
51 cell infiltration, faster vascular regression, and lower density of fibroblasts compared to a placebo group  
52 [14]. From a biomechanical standpoint, previous studies related to Achilles tendon repair have used PRP

53 preparation in a rat or rabbit model [17,32,7,18]. In addition to using a different preparation than PRGF,  
54 the rat or rabbit model has obvious differences in tendon size (length and thickness) compared to the  
55 human specie. Despite it has been demonstrated that PRGF produce improvements in healing of Achilles  
56 tendon repairs after histologic analysis, there is little evidence investigating the biomechanical effects of  
57 PRGF on the healing Achilles tendon in an animal model with tendon characteristics more similar to the  
58 human specie.

59           The purpose of this study was to assess whether the application of PRGF can improve the  
60 biomechanical properties of the Achilles tendon repair in sheep. It was hypothesized that the intra-  
61 tendinous injection of PRGF would improve force, section and tensile strength of the Achilles tendon  
62 repair compared to the injection of saline solution (placebo group).

63

## 64 **MATERIALS AND METHODS**

65

### 66 **Procedures**

67 This study was approved by the Bioethics Committee for animal research at the XXXXXX. The animal  
68 model was the young healthy adult merino female sheep between 45 Kg and 55 Kg of body weight  
69 without orthopedic disorders. A total of 30 animals were randomly assigned into 1 of the 6 groups (5  
70 animals per group) depending on the type of treatment received (PRGF or placebo) and survival time (2,  
71 4 and 8 weeks). After sectioning and suturing the Achilles tendon, half of the animals were treated with  
72 intra-tendinous injection of PRGF and half with intra-tendinous injection of saline solution. Animals were  
73 sacrificed at weeks 2, 4 or 8. For each study period, the tendon force, section, and tension were measured  
74 in the operated and contralateral healthy Achilles tendons. These biomechanical variables were then  
75 compared among all groups. The sheep model employed in this study is considered suitable to study  
76 Achilles tendon repairs because of easy surgical access, similar length and thickness compared to human  
77 Achilles tendons, and adequacy for biomechanical testing [4,22].

78

### 79 **Treatment groups**

80 The animals were placed under general anesthesia and had their right hind limbs aseptically prepared for  
81 surgery. An approach was made to the Achilles tendon by accessing its lateral face at approximately 2 cm  
82 from the calcaneal tuberosity and was extended 8 cm approximately. The surrounding fascia was released  
83 and the paratenon was cut longitudinally, clearly exposing the Achilles tendon (Figure 1A). Then, with  
84 the help of a ruler, a mark was made 5cm from the insertion of the tendon into the calcaneus tuberosity.  
85 Before performing the tenotomy, a pre-suture was placed using a triple pulley pattern (Figure 1B). This  
86 triple pulley pattern suture was done in a standardized manner using a non-absorbable monofilament  
87 (polypropylene) (Premilene USP 1, B Braun Aesculap, Melsungen, Germany). The tenotomy was then  
88 performed 5 cm proximal to the Achilles tendon insertion at the level of the mark previously done. The  
89 suture was carefully tied and knotted ensuring that tendon edges were well positioned (Figure 1C).  
90 Subsequently, an intra-operative, intra-tendinous PRGF or saline solution injection was applied using a  
91 23G gauge needle. A total of 1 ml was administered in each tendon edge. Finally, the wounds were closed  
92 using a simple discontinuous pattern. An external trans-articular fixator was placed connecting the tibia  
93 and the tarsus setting the ankle joint to be locked at an angle of 140° (Figure 1D) to ensure enough  
94 immobilization and to not compromise the tendon repair.

95 PRGF Endoret ® system (Biotechnology Institute [BTI], Vitoria, Spain) was used for obtaining  
96 PRGF. Four 5ml blood tubes containing 0.5 mL of 3.8% sodium citrate as anticoagulant were extracted.  
97 The blood was then centrifuged at 630G for a period of 8 minutes. After centrifugation, three different  
98 blood fractions were separated according to density: a plasma fraction, an intermediate line corresponding  
99 to leukocyte, and an erythrocyte sediment. A total of 0.5 ml of PRGF from the plasma portion that lies  
100 just above the leukocytic line was used. To obtain this portion, a process of pipetting fractionated in  
101 laminar flow was used and a total of 2 ml of PRGF (0.5 ml from each of the 4 tubes) was obtained. PRGF  
102 were then loaded into a syringe, and prior to intra-tendinous application the platelets were activated by  
103 addition of calcium chloride [5,6].

104 In addition to the first intra-operative injection, all sheep received two (the animals sacrificed at  
105 2 weeks) or three (the rest of the animals) ultrasound-guided injections of PRGF or saline solution during  
106 the post-operative period on a weekly basis. Weekly physical and orthopedic examinations were  
107 performed and the degree of lameness was evaluated.

108

109 **Measurement methods**

110 Once the animals were sacrificed at weeks 2, 4 or 8, the external fixators were removed and both operated  
111 and healthy tendons (control) were extracted including the bone and all proximal muscular tissue. All  
112 tendons were placed in plastic bags with their own identification number, and each pair of tendons of the  
113 same animal was placed in a re-sealable numbered bag. The samples were frozen at -20°C and transported  
114 in an insulated container with dry ice (solid CO<sub>2</sub>) to the XXXXXXXXXX, where they were stored at -80°C  
115 until biomechanical testing was to be carried out.

116 A total of 60 tendons (20 for each study period) were obtained. Additionally, four more tendons  
117 from surplus sheep from other studies were used for calibration and preliminary biomechanical testing.  
118 These 4 extra tendons were used to identify limitations in the biomechanical measurement methods. The  
119 two limitations observed were the inclusion of bone structures and the tissue slippage. A decision was  
120 taken to remove the calcaneus from all samples. To avoid slippage, the samples were fixed to the testing  
121 machine using low profile knurled-surface clamps with deposits for the freezing fluid so that the whole  
122 tissue-clamp system can be frozen (Figure 2) [8].

123 Samples were thawed during the day before the test and placed in a refrigerator at +5°C. The  
124 calcaneus, excess muscle and suture used during the healing phase were removed. Each clamp was placed  
125 at 1.5cm from the tendon repair area (3 cm of space in between clamps). The samples were placed  
126 between the clamps wrapped with a surgical gauze and cotton cloth to prevent tissue contact with the  
127 metal. Then the clamps were fixed by uneven tightening of the screws and placed in the universal testing  
128 machine. System freezing began using laboratory grade acetone poured into the clamp deposits and  
129 adding solid CO<sub>2</sub> to gradually freeze the soft tissue-clamp system avoiding freezing of the tested area  
130 (Figure 2). The freezing process was monitored by a laser thermometer to prevent freezing of the tested  
131 area. After obtaining the freezing of the tissue-clamp system, the test was started at a tensile speed of  
132 0.4mm/s (Figure 3).

133 The biomechanical outcomes measured in the present study were the ratio of force, section, and  
134 tension between the operated and healthy tendons (expressed in %). The force ratio was obtained by  
135 dividing the maximum force in Newtons (N) of the operated tendon by the maximum force of the healthy  
136 tendon, and multiplied by 100. The section ratio was obtained by dividing the cross-sectional area in mm<sup>2</sup>  
137 of the operated tendon by the cross-sectional area of the healthy tendon, and multiplied by 100. The

138 tension ratio was obtained by dividing the maximum tension in megapascals (MPa) of the operated  
139 tendon by the maximum tension of the healthy tendon, and multiplied by 100. The tension was calculated  
140 by dividing the maximum breaking force recorded during the test by the section of the tested tendon.

141

## 142 **Statistical analysis**

143 Descriptive statistics were used to summarize values of force, section, and tension ratios in all groups.  
144 Before the inter-group statistical comparison for the biomechanical outcomes, tests for normality (using  
145 the Shapiro-Wilk test), and homogeneity of variances (using the Levene test) were conducted. The Dixon  
146 Q test was also used to identify and reject outlier values. Given the type of study, data independence  
147 could be assumed. A 2x3 (treatment by time) Analysis of Variance (ANOVA) was conducted to compare  
148 biomechanical variables with normal distribution among all groups. For non-normal distribution  
149 variables, a Kruskal-Wallis test was used for the inter-group comparison of biomechanical data. All  
150 statistical analyses were conducted with the software R (R Foundation for Statistical Computing, Vienna,  
151 Austria) The alpha level was set at 0.05.

152

## 153 **RESULTS**

154

155 No animals had to be discarded during the study. The mean (SD) duration of surgery was 51 minutes. The  
156 external fixation system remained intact throughout the postoperative period. Eight animals had clean  
157 discharge at the pins site without any sign of infection.

158 The mechanical anchorage with clamps and the freezing system was adequate to assure accurate  
159 biomechanical testing. No tissue slippage or failures in the tissue-clamp system occurred. The 3 cm  
160 distance between clamps during the test proved to be wide enough to prevent freezing of the test area and  
161 permitted getting close enough to analyze the scar area.

162 Table 1 summarizes the descriptive statistics for all biomechanical variables evaluated in the 3  
163 groups. The comparison among all groups for force ratio is shown on Figure 4. Two values were

164 considered outliers according to the Dixon Q test. At the 8-week period, the force ratio in the PRGF  
165 group was significantly higher compared to the placebo group ( $p=0.007$ ). PRGF and placebo treatments  
166 demonstrated significant increase in force ratio from 2 weeks to 8 weeks ( $p<0.001$  in both cases).

167 The comparison of section ratio among all groups is shown on Figure 5. None of the values were  
168 considered outliers after applying the Dixon Q test. There were no significant differences in section ratio  
169 between the use of PRGF and placebo for any of the study periods. The use of PRGF produced a  
170 significant increase in section ratio at 4 weeks compared to 2 weeks, and a significant reduction of section  
171 ratio at 8 weeks compared to 4 weeks.

172 The tension parameter had 2 outlier values according to the Dixon Q test. These values were  
173 kept to avoid a too low number of samples available for the analysis. At 2 weeks, the PRGF tension ratio  
174 was significantly higher ( $p=0.014$ ) compared to the placebo group (Figure 6). The treatment with PRGF  
175 produced a significant increase in tension from weeks 2 to 8, but also from weeks 2 to 4 and 4 to 8  
176 (Figure 6). PRGF and placebo treatments demonstrated higher tension ratio values at 8 weeks compared  
177 to 2 weeks ( $p=0.009$  and  $p=0.039$ , respectively) (Figure 6).

178

## 179 **DISCUSSION**

180

181 The principal finding of this study was the between-treatment differences for force ratio after Achilles  
182 tendon repair. The PRGF-treated tendons were biomechanically stronger compared to placebo-treated  
183 tendons. Section and tension ratios were essentially similar between treatment groups, except a higher  
184 tension ratio in the PRGF compared to the placebo group at 2 weeks.

185 The use of sheep is an adequate model for basic science investigations of Achilles tendon  
186 injuries. The dimensions of the Achilles tendon of the sheep provide enough tissue to perform  
187 biomechanical testing, and it is similar in size (length and thickness) to the human Achilles tendon  
188 [22,26]. In addition, the weight of the sheep is closer to humans, as compared to the use of smaller  
189 animals previously employed (i.e., rats). The methods employed in this study in terms of tissue fixation,  
190 freezing and testing velocity share some similarities but also differences from previous studies. The

191 present study used external clamps for tissue fixation into the testing machine. Similar methods have been  
192 successfully employed in several other orthopedic experiments [12,14,28]. Previous studies with rat  
193 model have kept the tendon attachment to bone [17,32]. Given that the mechanically weakest point in  
194 preliminary testing was the tendon-to-bone attachment, a decision was made to remove the calcaneus.  
195 The freezing method employed in the present study differs from previous investigations using liquid  
196 nitrogen into the tanks of the clamp [8], or immersing clamp in liquid nitrogen [11,17,23,32]. Use of  
197 acetone and solid CO<sub>2</sub> was adequate to ensure an adequate tissue grip and avoid the freezing of the tested  
198 area. Liquid nitrogen provides a very fast freezing which may increase the risk of soft tissue freezing  
199 between the clamp. The testing velocity was based on previous studies [8]. Mechanical properties of  
200 tendons are affected by the testing velocity due to its viscoelastic characteristics [31]. Too high velocity  
201 testing was avoided because water is not removed from the tissue, increasing its rigidity [27].

202 Biomechanical studies usually involve force measurements through load cells of universal  
203 testing machines [15,21]. The decision to report the outcomes as ratio (in %) between operated and  
204 healthy tendons decreases the effect that variability between animals may have on the results [19]. The  
205 inclusion of the tension variable (force/section) makes the difference with other published studies, but  
206 also greatly complicates the analysis and interpretation of results. This variable is used in studies with all  
207 kinds of materials in which the section is maintained during the test [1,24]. However, tendons change  
208 their section as the tissue is stretched. Therefore, changes in section without changes in force may elicit  
209 different tension values. At the beginning of the test, tension is low as small force is applied over a large  
210 section, but as the tendon is stretched the section is reduced and the tension increases. Tension should be  
211 measured just before the tendon ruptures, giving the maximum tension value for a given section. The  
212 tension parameter was included in the present study because provides more information on the quality of  
213 the scar tissue that forms in the healing tendon.

214 The results of the present study show that tendons treated with PRGF are stronger at 8 weeks  
215 compared to placebo-treated tendons. This provides a biomechanical basis for the results obtained by  
216 Fernández-Sarmiento et al. [14], who observed a more elongated silhouette, more type-I collagen, and  
217 better core orientation of tendon fibroblasts with PRGF compared to placebo after 8 weeks (better  
218 histologic characteristics). In addition, the results observed in the present study for force ratio also  
219 support the results observed in other studies [4,26,31]. It was found that the use of PRP in Achilles tendon  
220 produced a faster maturity of the scar tissue in rats [17]. In fact, rats treated with PRP or placebo had



221 increased tendon resistance in the first weeks and later stabilized regardless of treatment [17], which  
222 corresponds to the findings of the present investigation. Interestingly, Kaux et al. also observed  
223 significantly higher force for PRP-treated animals compared to placebo at 8 weeks [17]. In the rat model,  
224 it has been concluded that the application of PRP improves the strength of the tendons until 42 days [29].  
225 However, caution must be taken when comparing the results of the present study with previous studies, as  
226 differences in the animal model or PRGF preparation may explain different results [14,6,29].

227 Overall, section ratios of the samples showed no significant differences among groups. However,  
228 section ratio in PRGF-treated tendons at 4 weeks was significantly higher compared to 2 and 8 weeks. It  
229 has been demonstrated that sections evidently change in the early days in the PRP-treated rats, and  
230 evened out after a longer time in the placebo-matched group [17]. This result means that the sizes of  
231 healing scars in the tenotomy areas do not vary significantly between week 2 and 8 for the placebo group.  
232 Our findings for section ratio changes were similar than the one observed by Kaux et al. in their rat model  
233 [17]. With PRGF, repair scars significantly increase from week 2 to 4 and then significantly decrease in  
234 size from weeks 4 to 8, whereas the placebo treatment shows no significant section changes throughout  
235 the study period. Time-related changes in section ratio in PRGF-treated tendons may be explained by an  
236 earlier initiation of the inflammatory and reparative processes with lower inflammatory infiltration at  
237 weeks 4 and 8 leading to early thickening [14].

238 The PRGF-treated tendons demonstrated significantly higher tension ratio at week 2 compared to  
239 placebo-treated tendons. Therefore, it may be interpreted that the scar tissue of tendons treated with  
240 PRGF withstands more force per unit area. This may indicate a higher quality of the scar tissue in tendons  
241 treated with PRGF compared to those treated with placebo. This would coincide with the results of  
242 Fernández-Sarmiento et al. [14], where tendons treated with PRGF proved to have an earlier period of  
243 maturity and matured faster than those treated with saline solution, despite histologic studies at week 2.  
244 Although histologic analysis was not carried out in the present investigation, it is reasonable to expect  
245 that better collagen fibers and structure would confer an increased resistance of the scar tissue [14]. It has  
246 also been shown that PRGF-treated supraspinatus tendons in rats produce an early improved resistance of  
247 the tendon and a greater infiltration of fibroblast and greater alignment of fibroblast in the longitudinal  
248 axis of the tendon [9]. The placebo-treated tendons exhibited a significant increase in tension ratio from  
249 week 2 to 4, but not from 4 to 8 weeks, whereas the PRGF-treated tendons significantly increased tension  
250 between all time periods. This can be interpreted as an improvement in the tissue quality of tendons

251 treated with PRGF, causing the tension ratio to gradually progress from 2 to 8 weeks. This could  
252 correspond with previous histological studies on the effects of PRGF using the same animal model [14].

253           This study has some limitations. First, the sample size was small. This may explain the absence  
254 of significant between-treatment differences at some time periods where a trend towards significance was  
255 observed (force ratio at 2 weeks). Second, the presence of abnormal high or low values (highly dispersed  
256 values) may explain the absence of significant differences in studies with small sample size. Although the  
257 Dixon Q test was employed to rule out outliers, other values not classified as outliers but obviously high  
258 or low were not discarded as to not further decrease the sample size. Third, tension was a calculated  
259 rather than a measured parameter. Therefore, abnormal force and section values affected the final tension  
260 ratio values. However, tension was relevant to calculate because provides further information on how a  
261 certain section resists forces, which may be related to the quality of the scar tissue. On the other hand, this  
262 study provides valuable information on the biomechanical effects of PRGF on Achilles tendon repair in  
263 an in-vivo model. In addition, this study uses an animal model closer to humans and evaluates both early  
264 (2 weeks) and late (8 weeks) biomechanical effects.

265

## 266 **Conclusion**

267 The application of PRGF improves the strength of the Achilles tendon repair at eight weeks compared to  
268 application of saline solution. PRGF can be used in the clinical setting as a complementary therapy to  
269 improve the treatment of acute Achilles tendon ruptures. The clinical relevance of this study is that PRGF  
270 can be used in the clinical setting as a complementary therapy to improve the repair strength of acute  
271 Achilles tendon ruptures.

272

- 274 1. Ajaxon I, Persson C (2014) Compressive fatigue properties of a commercially available acrylic  
275 bone cement for vertebroplasty. *Biomech Model Mechanobiol* 13 (6):1199-1207.
- 276 2. Andia I, Sanchez M, Maffulli N (2010) Tendon healing and platelet-rich plasma therapies.  
277 *Expert Opin Biol Ther* 10 (10):1415-1426.
- 278 3. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT (2004) Autologous platelets as a source of  
279 proteins for healing and tissue regeneration. *Thromb Haemost* 91 (1):4-15.
- 280 4. Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, Orive G, Azofra J, Andia I  
281 (2006) Autologous fibrin matrices: a potential source of biological mediators that  
282 modulate tendon cell activities. *J Biomed Mater Res A* 77 (2):285-293.
- 283 5. Anitua E, Sanchez M, Orive G, Andia I (2007) The potential impact of the preparation rich in  
284 growth factors (PRGF) in different medical fields. *Biomaterials* 28 (31):4551-4560.
- 285 6. Anitua E, Sanchez M, Orive G, Andia I (2009) Shedding light in the controversial terminology  
286 for platelet rich products. *J Biomed Mater Res A* 90 (4):1262-1263.
- 287 7. Aspenberg P, Virchenko O (2004) Platelet concentrate injection improves Achilles tendon  
288 repair in rats. *Acta Orthop Scand* 75 (1):93-99.
- 289 8. Baums MH, Buchhorn GH, Spahn G, Poppendieck B, Schultz W, Klinger HM (2008)  
290 Biomechanical characteristics of single-row repair in comparison to double-row repair  
291 with consideration of the suture configuration and suture material. *Knee Surg Sports*  
292 *Traumatol Arthrosc* 16 (11):1052-1060.
- 293 9. Beck J, Evans D, Tonino PM, Yong S, Callaci JJ (2012) The biomechanical and histologic  
294 effects of platelet-rich plasma on rat rotator cuff repairs. *Am J Sports Med* 40 (9):2037-  
295 2044.
- 296 10. Bennett NT, Schultz GS (1993) Growth factors and wound healing: biochemical properties  
297 of growth factors and their receptors. *Am J Surg* 165 (6):728-737
- 298 11. Bowser JE, Elder SH, Rashmir-Raven AM, Swiderski CE (2011) A cryogenic clamping  
299 technique that facilitates ultimate tensile strength determinations in tendons and  
300 ligaments. *Vet Comp Orthop Traumatol* 24 (5):370-373.
- 301 12. Bruce WJ, Frame K, Burbidge HM, Thompson K, Firth EC (2002) A comparison of the effects  
302 of joint immobilisation, twice-daily passive motion and voluntary motion on articular  
303 cartilage healing in sheep. *Vet Comp Orthop Traumatol* 15:23-29
- 304 13. Fenwick SA, Hazleman BL, Riley GP (2002) The vasculature and its role in the damaged and  
305 healing tendon. *Arthritis Res* 4 (4):252-260
- 306 14. Fernandez-Sarmiento JA, Dominguez JM, Granados MM, Morgaz J, Navarrete R, Carrillo JM,  
307 Gomez-Villamandos RJ, Munoz-Rascon P, Martin de Las Mulas J, Millan Y, Garcia-  
308 Balletbo M, Cugat R (2013) Histological study of the influence of plasma rich in growth  
309 factors (PRGF) on the healing of divided Achilles tendons in sheep. *J Bone Joint Surg*  
310 *Am* 95 (3):246-255.
- 311 15. Hettrich CM, Gasinu S, Beamer BS, Stasiak M, Fox A, Birmingham P, Ying O, Deng XH, Rodeo  
312 SA (2014) The effect of mechanical load on tendon-to-bone healing in a rat model. *Am*  
313 *J Sports Med* 42 (5):1233-1241.
- 314 16. Jarvinen TA, Kannus P, Maffulli N, Khan KM (2005) Achilles tendon disorders: etiology and  
315 epidemiology. *Foot Ankle Clin* 10 (2):255-266.
- 316 17. Kaux JF, Drion PV, Colige A, Pascon F, Libertiaux V, Hoffmann A, Janssen L, Heyers A,  
317 Nusgens BV, Le Goff C, Gothot A, Cescotto S, Defraigne JO, Rickert M, Crielaard JM  
318 (2012) Effects of platelet-rich plasma (PRP) on the healing of Achilles tendons of rats.  
319 *Wound Repair Regen* 20 (5):748-756.
- 320 18. Kim HJ, Nam HW, Hur CY, Park M, Yang HS, Kim BS, Park JH (2011) The effect of platelet  
321 rich plasma from bone marrow aspirate with added bone morphogenetic protein-2 on  
322 the Achilles tendon-bone junction in rabbits. *Clin Orthop Surg* 3 (4):325-331.

- 323 19. Kim MY, Farnebo S, Woon CY, Schmitt T, Pham H, Chang J (2014) Augmentation of tendon  
324 healing with an injectable tendon hydrogel in a rat Achilles tendon model. *Plast*  
325 *Reconstr Surg* 133 (5):645e-653e.
- 326 20. Maganaris C, Narici M, Almekinders L, Mafulli N (2007) Biomechanics of the Achilles  
327 tendon. In: Mafulli N, Almekinders L (eds) *The Achilles tendon*. Springer, London, pp  
328 17-24
- 329 21. Manning DW, Spiguel AR, Mass DP (2010) Biomechanical analysis of partial flexor tendon  
330 lacerations in zone II of human cadavers. *J Hand Surg* 35 (1):11-18.
- 331 22. Martini L, Fini M, Giavaresi G, Giardino R (2001) Sheep model in orthopedic research: a  
332 literature review. *Comp Med* 51 (4):292-299
- 333 23. Monto RR (2012) Platelet rich plasma treatment for chronic Achilles tendinosis. *Foot Ankle*  
334 *Int* 33 (5):379-385.
- 335 24. Musani S, Musani I, Dugal R, Habbu N, Madanshetty P, Virani D (2013) An in vitro  
336 Comparative Evaluation of Micro Tensile Bond Strength of Two metal bonding Resin  
337 Cements bonded to Cobalt Chromium alloy. *J Int Oral Health* 5 (5):73-78
- 338 25. O'Brien M (2005) The anatomy of the Achilles tendon. *Foot Ankle Clin* 10 (2):225-238.
- 339 26. Pearce AI, Richards RG, Milz S, Schneider E, Pearce SG (2007) Animal models for implant  
340 biomaterial research in bone: a review. *Eur Cell Mater* 13:1-10
- 341 27. Sammarco GJ, Burstein AH, Davis WL, Frankel VH (1971) The biomechanics of torsional  
342 fractures: the effect of loading on ultimate properties. *J Biomech* 4 (2):113-117
- 343 28. Skerry TM, Lanyon LE (1993) Immobilisation induced bone loss in the sheep is not  
344 modulated by calcitonin treatment. *Bone* 14 (3):511-516
- 345 29. Solchaga LA, Bendele A, Shah V, Snel LB, Kestler HK, Dines JS, Hee CK (2014) Comparison of  
346 the effect of intra-tendon applications of recombinant human platelet-derived growth  
347 factor-BB, platelet-rich plasma, steroids in a rat achilles tendon collagenase model. *J*  
348 *Orthop Res* 32 (1):145-150.
- 349 30. Uysal CA, Tobita M, Hyakusoku H, Mizuno H (2012) Adipose-derived stem cells enhance  
350 primary tendon repair: biomechanical and immunohistochemical evaluation. *J Plast*  
351 *Reconstr Aesthet Surg* 65 (12):1712-1719.
- 352 31. Wang JH, Guo Q, Li B (2012) Tendon biomechanics and mechanobiology--a minireview of  
353 basic concepts and recent advancements. *J Hand Ther* 25 (2):133-140; quiz 141.
- 354 32. Wnuk T, Blacha J, Mazurkiewicz T, Olchowik G, Chyzynska M (2012) The mechanical and  
355 histological estimation of calcaneal tendon callus in rats after PRP injection. *Pol Orthop*  
356 *Traumatol* 77:5-9

357

PERIOD (weeks)	GROUP	N	Mean (SD), in %	Range, in %
<b>FORCE RATIO</b>				
2	PCB	4	2.5 (0.3)	2.1-2.9
2	PRGF	5	5.2 (2.8)	2.7-9.6
4	PCB	5	18.2 (8.8)	4.7-28.4
4	PRGF	5	18.7 (6.5)	9.5-24.8
8	PCB	4	15.1 (1.4)	13.5-16.6
8	PRGF	5	26.3 (5.8)	19.1-32.6
<b>SECTION RATIO</b>				
2	PCB	4	216.1 (24.9)	191.3-245
2	PRGF	5	227.9 (74.1)	140.3-328.6
4	PCB	5	276.1 (91.1)	124.3-352.6
4	PRGF	5	416.7 (113.5)	258.5-528.3
8	PCB	4	249.2 (90.2)	166.7-375.5
8	PRGF	5	286.6 (52.2)	208.2-341
<b>TENSION RATIO</b>				
2	PCB	4	1.2 (0.2)	1-1.4
2	PRGF	5	2.3 (0.9)	1.6-3.9
4	PCB	5	6.2 (1.6)	3.8-8.1
4	PRGF	5	4.8 (1.7)	1.8-5.8
8	PCB	4	6.6 (2.3)	3.8-9.4
8	PRGF	5	9.7 (3.8)	6.4-15.7

359 **Table 1.** Descriptive statistics for force, section, and tension ratios between operated and healthy tendons

360 across all groups

361 PCB, placebo; PRGF, platelet-rich growth factors

362

363 **Figure legends**

364 **Figure 1.** Procedure for the section, suture and immobilization of operated tendon.

365 Panel A. Dissection of the fascia overlying the Achilles tendon.

366 Panel B. Pre-tendon suture. The various loops that make up the pattern in triple pulley are made. Each of  
367 the loops is placed in a flat 120° from the previous loop, so that they are will never be in the same plane.

368 Panel C. Knotted suture demonstrating the adequate apposition of the tendon edges.

369 Panel D. Implantation of the external fixator. Pins at the tibia and metatarsus are connected together at an  
370 angle of 140°.

371 **Figure 2.** Freezing of the system using laboratory grade acetone poured into the clamp deposits and  
372 adding solid CO<sub>2</sub>.

373 **Figure 3.** Final assembly of the clamp jaws in the testing machine.

374 **Figure 4.** Force ratio values between operated tendon and healthy tendon across all groups.

375 **Figure 5.** Section ratio values between operated tendon and healthy tendon across all groups.

376 **Figure 6.** Tension ratio between operated tendons and healthy tendons across all groups.